A case of euglycemic diabetic ketoacidosis due to empagliflozin use in a patient with type 1 diabetes mellitus

Basit Öğe Kaydı
dc.authorid0000-0003-2811-0052en_US
dc.authorid0000-0002-3836-2125en_US
dc.authorid0000-0001-7306-5233en_US
dc.authorid0000000299005981en_US
dc.authorid0000-0002-4162-5563en_US
dc.contributor.authorBilgin, Satılmış
dc.contributor.authorDuman, Tuba Taşlamacıoğlu
dc.contributor.authorKurtkulağı, Özge
dc.contributor.authorYılmaz, Feyza
dc.contributor.authorAktaş, Gülali
dc.date.accessioned2023-07-24T12:03:37Z
dc.date.available2023-07-24T12:03:37Z
dc.date.issued2022en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractEuglycemic diabetic ketoacidosis is characterised by serum blood glucose <250 mg/dl, arterial blood pH <7.35, and the presence of ketones in urine or blood. Here, we present a 36-year female with type-1 diabetes mellitus, a case of euglycemic diabetic ketoacidosis, who was admitted to the emergency unit with nausea, vomiting, and confusion after using empagliflozin, which was added to her treatment one month ago. She was followed up in the intensive care unit for four days. Empagliflozin was discontinued. Intravenous fluids and insulin infusions were given. The patient, whose metabolic acidosis regressed, was discharged with the necessary recommendations and training. Euglycemic diabetic ketoacidosis should be kept in mind as a differential diagnosis in patients with type-1 diabetes and type-2 diabetes presenting with acidosis. Attention should be paid to the patients??? medications and whether there are SGLT-2 inhibitors among these drugs.en_US
dc.identifier.citationBilgin, S., Duman, T. T., Kurtkulagi, O., Yilmaz, F., & Aktas, G. (2022). A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus. J Coll Physicians Surg Pak, 32(7), 928-930.en_US
dc.identifier.doi10.29271/jcpsp.2022.07.928
dc.identifier.endpage930en_US
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.issue7en_US
dc.identifier.pmid35795946en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage928en_US
dc.identifier.urihttp://dx.doi.org/10.29271/jcpsp.2022.07.928
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11345
dc.identifier.volume32en_US
dc.identifier.wosWOS:000822704300020en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorBilgin, Satılmış
dc.institutionauthorDuman, Tuba Taşlamacıoğlu
dc.institutionauthorAktaş, Gülali
dc.language.isoenen_US
dc.publisherColl Physicians & Surgeons Pakistanen_US
dc.relation.ispartofJcpsp-Journal of the College of Physicians and Surgeons Pakistanen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectSodium-Glucose Co-Transporter-2 Inhibitorsen_US
dc.subjectEuglycemic Diabetic Ketoacidosisen_US
dc.subjectEmpagliflozinen_US
dc.subjectSGLT-2en_US
dc.subjectArterial Blooden_US
dc.titleA case of euglycemic diabetic ketoacidosis due to empagliflozin use in a patient with type 1 diabetes mellitusen_US
dc.typeCase Reporten_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
satilmis-bilgin.pdf
Boyut:
141.72 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu